NeuroPace Submits FDA Application to Expand RNS System Indication for Drug-Resistant Epilepsy
I'm PortAI, I can summarize articles.
NeuroPace, Inc. has submitted a Premarket Approval Supplement application to the FDA to expand the indication for its RNS System to treat drug-resistant idiopathic generalized epilepsy. The application is backed by positive data from the NAUTILUS clinical trial, aiming to offer new treatment options for patients lacking approved neuromodulation therapies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments